The next breakthrough in Alzheimer’s research could come from old and ‘cognitively impaired’ Chilean rats

Tristan Bove

Among the animals you might consider useful to understanding the degenerative effects of Alzheimer’s, a species of long-lived rodent found in the woodlands of Chile probably did not make the list.<div class="paywall-selector"></div><div class="paywall">



Not as well-known as its cousins the chinchilla or the guinea pig, Octodon degus, also known as the common degu, is a rodent endemic to the forested valleys of central Chile with a propensity for especially long life spans among its kind, reaching up to eight years of age. 



But what the small rat lacks in fame it may more than make up for in its value to scientists studying the degenerative neurological symptoms of Alzheimer’s, one of the world’s most devastating ailments that causes irreversible cognitive decline and dementia, treatment for which has eluded medical researchers for <a href="https://theconversation.com/why-dont-we-have-a-cure-for-alzheimers-disease-156473">more than a century</a> since its discovery.



Elderly degus exhibiting signs of cognitive decline provide an ideal model for researchers to study the effects of one of the most common forms of Alzheimer’s disease or AD, scientists from the University of California at Irvine write in a new <a href="https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-022-01481-x">study</a> published this week in the medical journal Acta Neuropathologica Communications.



The researchers observed a colony of 146 degus who were getting on in years and put them all through a test to evaluate their cognitive abilities. The experiment involved placing food pellets in an artificial burrow, and degus would pass or fail the test based on how many pellets they were able to retrieve in a given time.&nbsp;



Degus who were unsuccessful in the pellet retrieval mission were designated as exhibiting “AD-like” behavior. Upon completion of the test, 12 unlucky degus, six with AD tendencies and six without, were euthanized before their brains were collected and analyzed by researchers.&nbsp;



They concluded that, based on the behavior of AD-like degus, the species is a “natural model” for human Alzheimer’s disease, and specifically of “sporadic” Alzheimer’s, by far the <a href="https://alzheimer.ca/sites/default/files/documents/research_understanding-genetics-and-alzheimers-disease.pdf">most common form of the disease</a> which does not run in families and can emerge as an unfortunate combination of genetics, environment, and lifestyle, making it much harder to identify before onset. Of the 44 million people suffering from Alzheimer’s worldwide, over 90% of cases occur sporadically, according to the study.



“We found robust neurodegenerative features in cognitively impaired aged degus,” Xiangmin Xu, a professor in anatomy and neurobiology at UCI and corresponding author for the study, said in a <a href="https://www.sciencedaily.com/releases/2022/12/221219164833.htm">statement</a>, adding the behavior was “consistent with the neural circuit hyperactivity that [is] commonly reported in human Alzheimer’s disease patients.”



Degus research will be useful in tracing the development and symptoms of sporadic Alzheimer’s, the authors wrote, adding it will help to understand comorbidities, diseases that can appear simultaneously with Alzheimer’s. The researchers identified evidence of Type 2 diabetes, macular degeneration affecting eyesight, and sclerosis in degus’ arteries.



<a href="https://journals.sagepub.com/doi/10.1177/1756285612461679">Only symptomatic treatments</a> that can temporarily dampen Alzheimer’s effects are currently available. There is <a href="https://www.nhs.uk/conditions/alzheimers-disease/treatment/#:~:text=There's%20currently%20no%20cure%20for,family%2C%20cope%20with%20everyday%20life.">no existing cure</a> for the disease, and efforts and trials to cure or prevent the disease have so far <a href="https://www.mdpi.com/2227-9059/7/4/97">mostly ended in failure</a>. 



But earlier this year, hopes that the tragic disease could be reversed were revived when encouraging results from trials of a new medicine were published. The treatment, known as lecanemab, was found to <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02480-1/fulltext">reduce cognitive decline</a> in patients exhibiting signs of Alzheimer’s by 27% compared with placebos.



Doubts remain about the new treatment’s safety, as <a href="https://www.science.org/content/article/scientists-tie-third-clinical-trial-death-experimental-alzheimer-s-drug">three deaths</a> have so far been tied to the experimental drug. Trial investigators found evidence of “brain swelling and microhemorrhages” that may have led to the deaths. 



The drug is <a href="https://www.google.co.uk/search?q=lecanemab+lobbying+further+tests&amp;sxsrf=ALiCzsbGkSGVW9q3EIPYcb0KN2k6Ns-A4A:1671723901719&amp;source=lnms&amp;tbm=nws&amp;sa=X&amp;ved=2ahUKEwjb58vqyI38AhUT57sIHTH-C1AQ_AUoAXoECAEQAw&amp;biw=1440&amp;bih=694&amp;dpr=2">currently under FDA review</a>.</div>

Similar symptoms to human Alzheimer’s were observed in Chilean degus, providing an avenue to understand symptoms and comorbidities.

Alzheimer’s research boosted by study involving Chilean rodent

A Chilean degu rodent sitting on a forest branch

Our new weekly Impact Report newsletter examines how ESG news and trends are shaping the roles and responsibilities of today's executives. <a href="https://mynewsletters.fortune.com/impact-report">Subscribe here</a>.

F-BreakingNews

Alzheimer's

Health

Researchers trying to understand human Alzheimer’s may have a lot to learn from the Chilean degu.

A small Chilean rat could be the next step forward for Alzheimer’s research

Alzheimer’s research boosted by study involving Chilean rodent | Fortune

Susan Jaffe

KFF Health News

Breakups between health systems and Medicare Advantage plans have increased. Sometimes, patients get to leave plans, too

/well/2025/04/24/medicare-advantage-patients-leave-plan-health-system-breakup/

Beth Greenfield

Father with one arm around daughter and another holding a basketball

Happier parents tap into this 1 emotion

/well/2025/04/23/happy-parents-awe-pride-study/

Alexa Mikhail

Here are the top 10 best and worst states for older adults in the workplace

/well/2025/04/23/best-worst-states-older-adult-workers/

Ani Freedman

Childhood exposure to this bacteria could be driving rates of colorectal cancer in millennials and Gen Xers, new study warns

/well/article/childhood-exposure-bacteria-colorectal-cancer-rates-millennials-gen-xers/

Paying attention to these 14 risk factors can reduce your risk of dementia, science says

/well/article/dementia-risk-factors-prevention/

What is stage 0 breast cancer? Tina Knowles, recently diagnosed and treated for stage 1, said she’d never heard of it—and she’s not alone

/well/2025/04/22/tina-knowles-stage-0-breast-cancer/

Shawn Tully

The new leader of the Catholic Church will inherit a financial mess that Pope Francis spent much of his reign trying to fix

https://fortune.com/article/pope-francis-vatican-finances-reform/?itm_source=parsely-api

Emma Burleigh

CEO of $65 billion software giant Workday's warning: 'There's nothing more dangerous than yesterday's success'

https://fortune.com/article/workday-ceo-carl-eschenbach-career-advice-dangerous-success-failure/?itm_source=parsely-api

Amanda Gerut

Elon Musk was supposed to work in government as a special employee for 130 days. He just pledged to spend ‘a day or two’ per week for the remainder of Trump’s 4-year term

https://fortune.com/article/elon-musk-special-government-employee-doge-trump-countdown/?itm_source=parsely-api

Matt Sedensky

The Associated Press

Elon Musk’s DOGE is claiming victory after uncovering $382 million in unemployment fraud—but the government already found it years ago: ‘I don’t think it’s news to anyone’

https://fortune.com/2025/04/15/elon-musk-doge-unemployment-fraud-claims/?itm_source=parsely-api

Preston Fore

Ralph Lauren’s CEO says he doesn't believe in sugar coating criticism—here's how he handles negative feedback with staff

https://fortune.com/article/ralph-lauren-ceo-patrice-louvet-addressing-workplace-feedback-strengths-weaknesses/?itm_source=parsely-api

Jim Edwards

‘The Sell America Trade’: Who's behind the sinking of the U.S. dollar

https://fortune.com/article/why-is-us-dollar-sinking/?itm_source=parsely-api